Clinical trials: Gene Mutation
- Condition Gene Mutation
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Bioavailability Heathy Volunteers
Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
- Trial name
- NCT01887626
- Testing
- Ticagrelor 90 mg whole tablet, Ticagrelor 90 mg tablet crushed, Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID, SARS-CoV2
Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR
The current coronavirus disease pandemic has posed a problem and a challenge for health systems globally. In the framework of a pandemic, a diagnosis is a key tool in containing and monitoring disease outbreaks.
- Conditions
- COVID, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04468217
- Testing
- Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples
- Where
- Chile
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Neurognos
Melanoma, BRAF V600 Mutation
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05810740
- Testing
- Binimetinib 15 MG, Binimetinib 45 MG
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Measles, Mumps
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
This study will compare the safety, tolerability, and immunogenicity of measles, mumps, rubella, and varicella (MMRV) vaccine made with an alternative manufacturing process with those of the 2006 process
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT01536405
- Testing
- MMRV (AMP), MMRV (2006 process)
- Volunteers
- 1,412 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malaria
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
- Trial name
- NCT07036159
- Testing
- RTS,S/AS01E vaccine
- Where
- 2 sites in Rwanda
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Non-small Cell Lung Cancer, EGFR Mutation
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
Researchers are looking for a better way to treat men who have advanced non-small cell lung cancer (NSCLC). NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body.
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Trial name
- NCT06221475
- Testing
- BAY2927088 coated tablet 10 mg, [14C]-BAY2927088 solution for infusion, [14C]-BAY2927088 oral solution
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bayer
Ocular Physiology
Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock
This will be a single-visit, randomized, double-masked, bilateral wear, non-dispensing, 2-sequence × 2-period crossover study to evaluate subject reported ocular symptoms.
- Trial name
- NCT05713552
- Testing
- Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock, Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Infertility
Comparison of Alternative Embryo Culture Systems
This study will compare two alternative embryo culture systems. Embryos from each patient will be randomly assigned to one of two systems. One group will be cultured conventionally in oil-covered droplets in dishes.
- Trial name
- NCT02028897
- Testing
- Conventional embryo culture, Enclosed embryo culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bruce Shapiro M.D.
Dental Caries
Population-centered Risk- and Evidence-based Dental Inter-professional Care Team
The main goal of the payment and delivery system reform is to reduce disparities in oral health and dental care access of low-income mothers and children living in rural Oregon counties.
- Trial name
- PREDICT (NCT02312921)
- Testing
- PREDICT
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Advantage Dental Services, LLC
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or…
- Trial name
- NCT01462357
- Testing
- Cervarix, Gardasil
- Where
- 21 sites in France, Hong Kong and 2 more
- Volunteers
- 1,079 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease
LRRK2 Mutation and Parkinson's Disease
The Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in autosomal dominant Parkinson's disease (PKD). An inhibitor for the leucine-rich repeat kinase 2 (LRRK2) is in pre-clinical development for potential use in treating…
- Trial name
- NCT01424475
- Testing
- Healthy, PKD Patients
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia With FLT3/ITD Mutation
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg.
- Trial name
- XY0206-CQT (NCT07162116)
- Testing
- XY0206, Moxifloxacin (400 mg)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Skin Aging
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
This study will evaluate the efficacy of the DIME TBT Cream in improving the appearance and hydration of aged skin in comparison to a retinol cream. This study will last for 60 days.
- Trial name
- NCT06125912
- Testing
- Dime Beauty TBT Cream, Positive Control
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Dime Beauty Co.
Body Fat Disorder
CoolSculpting of the Flank With Alternate Treatment Parameters
The purpose of this study is to evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction with an alternative treatment parameter.
- Trial name
- NCT02081196
- Testing
- The Zeltiq CoolSculpting System
- Where
- 3 sites in United States, Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Genetic Disease, Nonsense Mutation
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers
- Trial name
- NCT03309605
- Testing
- ELX-02
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Genetic Disease, Nonsense Mutation
Phase 1 Study of ELX-02 in Healthy Adults
Phase 1 Single Ascending Dose Study in Normal Healthy Volunteers
- Trial name
- NCT03292302
- Testing
- ELX-02
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Autoimmune Diseases
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
Previous clinical studies of immediate release (IR) formulations of GSK2982772 resulted in a high peak to trough ratio of GSK2982772.
- Trial name
- NCT03649412
- Testing
- GSK2982772 Modified Release, GSK2982772 Immediate Release
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Vaccines
Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)
The aim of the study is to assess the safety \& immunogenicity of a pandemic influenza vaccine administered at 2 different time points. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
- Trial name
- NCT00430521
- Testing
- Pandemic influenza vaccine (GSK1119711A)-formulation 1, Pandemic influenza vaccine (GSK1119711A)-formulation 2
- Where
- 10 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cirrhosis
Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects
The disposition of NRL972 after a 15-second intravenous injection of 2 mg NRL972 is distinctly slower in patients with hepatic cirrhosis and acute hepatitis than in healthy control subjects.
- Trial name
- NCT01164332
- Testing
- NRL972
- Where
- Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Norgine